FY2027 EPS Estimates for Roche Decreased by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Erste Group Bank reduced their FY2027 earnings per share estimates for Roche in a research note issued on Wednesday, March 4th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.48 per share for the year, down from their prior forecast of $3.50. The consensus estimate for Roche’s current full-year earnings is $2.81 per share.

RHHBY has been the subject of a number of other reports. The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a research report on Thursday, January 15th. Morgan Stanley reiterated an “underweight” rating on shares of Roche in a report on Wednesday, February 4th. JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a report on Monday, December 8th. Citigroup started coverage on shares of Roche in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. Finally, Wolfe Research reiterated an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Roche has a consensus rating of “Hold” and an average price target of $57.00.

Roche Trading Down 2.2%

Shares of RHHBY opened at $53.44 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. The stock’s 50-day moving average price is $56.02 and its 200-day moving average price is $48.88. Roche has a 52 week low of $34.75 and a 52 week high of $60.85.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of RHHBY. Curio Wealth LLC acquired a new stake in shares of Roche during the third quarter worth $25,000. Oakworth Capital Inc. acquired a new stake in shares of Roche in the 3rd quarter worth $57,000. First Horizon Advisors Inc. boosted its holdings in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock valued at $75,000 after acquiring an additional 826 shares in the last quarter. Salomon & Ludwin LLC increased its stake in shares of Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock worth $129,000 after acquiring an additional 2,053 shares during the period. Finally, Atlas Capital Advisors Inc. purchased a new position in Roche during the fourth quarter worth about $192,000.

Trending Headlines about Roche

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Shareholder vote passed all board proposals at Roche’s Annual General Meeting, indicating governance stability and broad shareholder support. Read More.
• Neutral Sentiment: Roche and Genentech highlighted that the giredestrant combo showed a numerical PFS improvement and manageable safety, and the company plans to continue development and explore other combinations/indications — this tempers the outright clinical setback but doesn’t remove disappointment. Read More.
• Neutral Sentiment: Analyst commentary from H.C. Wainwright suggested Roche’s miss shouldn’t be read as directly affecting Olema’s OPERA‑02 program — useful context that may limit cross-company contagion in the biotech space. Read More.
• Negative Sentiment: PersevERA Phase III missed its primary endpoint (no statistically significant PFS improvement versus letrozole + palbociclib). Media coverage and the Genentech/Roche release drove earlier share weakness as investors repriced giredestrant’s near-term commercial prospects. Read More.
• Negative Sentiment: Analyst and market reactions: headlines noted share drops after the trial miss and at least one broker (Erste Group) lowered FY2027 EPS estimates, increasing near-term earnings risk. Read More. · Read More.
• Negative Sentiment: Short interest surged in February — reported short positions rose ~117% to ~6.05M shares as of Feb. 27 (days-to-cover ≈ 1.6). That signals increased bearish positioning and potential for volatility or follow‑on selling pressure. (No link available)

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.